Palatin Technologies (PTN) Stock Price, Quote & News

Company Profile

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequatel...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 495 2200

Website: palatin.com

Address:

11 Deer Park Drive, Suite 204, Monmouth Junction, United States

MSR67 Jan. 17 at 5:29 AM

$PTN this stock is dead weight lol

1 · Reply

DarkWatcher Jan. 16 at 2:32 PM

$PTN what’s up? Is ST glitching?

0 · Reply

DarkWatcher Jan. 15 at 8:16 PM

$PLTR can I ask a favor? Check out this song from a young kid I know. https://youtu.be/CFZXC9xOYjA?si=GGz3KpBSRkkM5QV3 If you like it, hit the like. He needs views with likes to move him to the next level. He does have a few other songs that are great too. But this is his first on apple music and Spotify. 😀 you can make it happen if you take the time. He needs a .5million views in the 1st month to get a record label. 👍$SOFI $PTN if ever person took the time. Then it could happen 🤘

1 · Reply

DarkWatcher Jan. 15 at 8:12 PM

$SQM check out this song… tell me what you think… it’s a young kid that is trying to get some eyes to acknowledge his talent. Please be one that does. Hit the like if you think the song is good! https://youtu.be/CFZXC9xOYjA?si=GGz3KpBSRkkM5QV3 $PTN $CYBL

0 · Reply

Rollercoaster22 Jan. 15 at 2:34 PM

$PTN

0 · Reply

DarkWatcher Jan. 14 at 3:34 PM

$PTN who thinks the Supreme Court will rule against the Trump administration today?

1 · Reply

Rollercoaster22 Jan. 14 at 6:36 AM

$PTN Janus Hendersen bought 170 097 shares at the end of 2025. Their average is $19,54 and they now own 9,99% in $PTN. I'm super

0 · Reply

WallStWireAds Jan. 13 at 11:17 PM

$PTN "Palatin Technologies Targets Hypothalamic Obesity as Next Frontier Beyond GLP-1s (NYSE: PTN)"

0 · Reply

JOHNB21400 Jan. 13 at 9:33 PM

$PTN Back to the upside with new recommendations by analysts.

0 · Reply

Rollercoaster22 Jan. 13 at 9:09 PM

$PTN Can only image how this stock will move with huge volume.

0 · Reply

Palatin Technologies, Inc. (PTN) Q1 2026 Earnings Call Transcript

Nov 13, 2025, 7:30 AM EST - 2 months ago

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Nov 12, 2025, 12:15 PM EST - 2 months ago

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

Nov 6, 2025, 8:00 AM EST - 2 months ago

Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity

Nov 6, 2025, 7:30 AM EST - 2 months ago

Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering

Sep 22, 2025, 7:30 AM EDT - 4 months ago

Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim

Aug 18, 2025, 8:05 AM EDT - 5 months ago

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases

Aug 8, 2025, 4:00 PM EDT - 5 months ago

Palatin Announces 1-for-50 Reverse Stock Split

Jul 15, 2025, 7:30 AM EDT - 6 months ago

Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity

May 15, 2025, 6:43 PM EDT - 8 months ago

Palatin Technologies, Inc. (PTN) Q3 2025 Earnings Call Transcript

May 14, 2025, 7:30 AM EDT - 8 months ago

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

May 9, 2025, 7:30 AM EDT - 9 months ago

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

May 8, 2025, 10:19 PM EDT - 9 months ago

Palatin Technologies Announces Closing of Reduced Public Offering

May 7, 2025, 8:26 PM EDT - 9 months ago

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

May 7, 2025, 5:20 PM EDT - 9 months ago

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)

May 7, 2025, 8:15 AM EDT - 9 months ago

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

May 7, 2025, 8:00 AM EDT - 9 months ago

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

May 5, 2025, 7:30 AM EDT - 9 months ago

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

Apr 29, 2025, 7:30 AM EDT - 9 months ago

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Apr 17, 2025, 7:30 AM EDT - 9 months ago

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Apr 14, 2025, 7:00 AM EDT - 9 months ago

Palatin Appeals NYSE American Notice of Delisting

Apr 10, 2025, 4:01 PM EDT - 10 months ago

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Apr 10, 2025, 7:30 AM EDT - 10 months ago

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Mar 31, 2025, 7:30 AM EDT - 10 months ago

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Mar 28, 2025, 7:30 AM EDT - 10 months ago

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Mar 25, 2025, 7:30 AM EDT - 10 months ago

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Feb 15, 2025, 5:41 AM EST - 11 months ago

Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript

Feb 13, 2025, 7:30 AM EST - 1 year ago

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Feb 10, 2025, 4:00 PM EST - 1 year ago

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Feb 7, 2025, 8:00 AM EST - 1 year ago

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Feb 6, 2025, 7:30 AM EST - 1 year ago

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Jan 28, 2025, 7:30 AM EST - 1 year ago

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Dec 19, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Dec 16, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

Nov 25, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

Nov 14, 2024, 12:49 PM EST - 1 year ago

Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript

Nov 14, 2024, 7:30 AM EST - 1 year ago

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Nov 8, 2024, 9:57 AM EST - 1 year ago

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Nov 4, 2024, 7:30 AM EST - 1 year ago

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Oct 7, 2024, 4:15 PM EDT - 1 year ago

Palatin Receives Notice of Non-Compliance from NYSE American

Oct 1, 2024, 2:55 PM EDT - 1 year ago

Palatin Technologies, Inc. (PTN) Q4 2024 Earnings Call Transcript

Oct 1, 2024, 7:30 AM EDT - 1 year ago

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Sep 26, 2024, 7:30 AM EDT - 1 year ago

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Aug 28, 2024, 7:30 AM EDT - 1 year ago

FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

Aug 22, 2024, 7:30 AM EDT - 1 year ago

First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

MSR67 Jan. 17 at 5:29 AM

$PTN this stock is dead weight lol

1 · Reply

DarkWatcher Jan. 16 at 2:32 PM

$PTN what’s up? Is ST glitching?

0 · Reply

DarkWatcher Jan. 15 at 8:16 PM

1 · Reply

DarkWatcher Jan. 15 at 8:12 PM

0 · Reply

Rollercoaster22 Jan. 15 at 2:34 PM

$PTN

0 · Reply

DarkWatcher Jan. 14 at 3:34 PM

$PTN who thinks the Supreme Court will rule against the Trump administration today?

1 · Reply

Rollercoaster22 Jan. 14 at 6:36 AM

$PTN Janus Hendersen bought 170 097 shares at the end of 2025. Their average is $19,54 and they now own 9,99% in $PTN. I'm super

0 · Reply

WallStWireAds Jan. 13 at 11:17 PM

$PTN "Palatin Technologies Targets Hypothalamic Obesity as Next Frontier Beyond GLP-1s (NYSE: PTN)"

0 · Reply

JOHNB21400 Jan. 13 at 9:33 PM

$PTN Back to the upside with new recommendations by analysts.

0 · Reply

Rollercoaster22 Jan. 13 at 9:09 PM

$PTN Can only image how this stock will move with huge volume.

0 · Reply

Jonita Jan. 13 at 8:51 PM

$PTN

0 · Reply

WallStWireAds Jan. 12 at 4:59 PM

$PTN www.benzinga.com/content/49847963/palatin-technologies-targets-hypothalamic-obesity-as-next-frontier-beyond-glp-1s-nyse-ptn

0 · Reply

DarkWatcher Jan. 12 at 1:33 PM

$PTN https://youtube.com/shorts/P3iK_0pQKmU?si=gQrt7SIjNuGkO3N5 when you grab the pebble little bull, it will be time to run! 😂🤣😂

0 · Reply

DarkWatcher Jan. 10 at 4:31 AM

$PTN this needs the power of the Hoax to get it going… I have a feeling it will happen soon… maybe in 3 weeks… 😅 count down has started!

0 · Reply

oooo_O Jan. 9 at 6:26 PM

$PTN $20 gets things going 😉

0 · Reply

Rollercoaster22 Jan. 9 at 8:50 AM

$PTN

0 · Reply

DarkWatcher Jan. 8 at 7:55 PM

$PTN https://youtu.be/QvUEUhgKcYE?si=fh--cF_PdmHPZJJe she splits… but it’s ok! Ptn rips!!! LFG!!!

0 · Reply

DarkWatcher Jan. 8 at 7:34 PM

$PTN soon this will take off!

0 · Reply

Rollercoaster22 Jan. 8 at 5:19 PM

$PTN Should have scaled down much, much earlier. Oh, well... Now it's done. Scaled down from $53 to $24, 22. LFG! 🤩

0 · Reply

WallStWireAds Jan. 8 at 2:14 PM

$PTN https://www.bioreview.com/hypothalamic-obesity-is-emerging-as-the-next-frontier-in-obesity-drug-development-and-palatin-is-worth-watching/

0 · Reply

DarkWatcher Jan. 8 at 8:21 AM

$PTN https://youtu.be/ViMk9WKT-dM?si=LNrcOdfuXznp1FWq 🤘🤘🤘🤘🤘

0 · Reply

DarkWatcher Jan. 8 at 6:16 AM

$PTN looks like a cup and handle… 😁🚀

0 · Reply

Market Cap	2.45M
Revenue (ttm)	4.49M
Net Income (ttm)	-29.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-662.36%
Debt to Equity Ratio	0.00

Volume	14,571,800
Avg Vol	3,131,146
Day's Range	N/A - N/A
Shares Out	26.01M
Stochastic %K	5%
Beta	0.94
Analysts	Strong Sell
Price Target	$7.00